@article{oai:hirosaki.repo.nii.ac.jp:00003573, author = {村上, 宏 and 玉澤, 直樹 and 大和, 一美 and 田辺, 壽太郎 and 葛西, 伸彦 and 松井, 淳 and 管, 静芝 and 小川, 吉司 and 須田, 俊宏}, issue = {3/4}, journal = {弘前医学}, month = {Mar}, note = {application/pdf, The effect of fenofibrate in type 2 diabetic patients with dyslipidemia was examined. Thirteen patients with type 2 diabetes mellitus and mixed hyperlipidemia; serum total cholesterol (TC)>220 mg/dl and/or triglyceride (TG)>150 mg/dl, were included in the study. Fenofibrate was administered at daily dose from 200 to 300 mg, and following items were implemented just prior to, at 3 months after, and at 6 months after the administration: amount of serum lipid, electrophoresis of lipoprotein by the method of polyacrylamide gel electrophoresis (PAGE), quantification of cholesterol (RLP-C) and triglyceride (RLP-TG) in remnant-like particle. TC significantly decreased at 6 months after administration (p